Age-adjusted comorbidity score stratifies mortality in prostate CA

Age-adjusted comorbidity score stratifies mortality in prostate CA

(HealthDay)—An age-adjusted prostate cancer-specific comorbidity index (PCCI) can stratify the risk of long-term nonprostate cancer-related mortality, according to a study published in the July issue of The Journal of Urology.

Timothy J. Daskivich, M.D., from the David Geffen School of Medicine at the University of California-Los Angeles, and colleagues sampled 1,598 men diagnosed with between 1998 and 2004. The authors determined the risk of nonprostate cancer-related mortality associated with age at diagnosis and PCCI score in testing and validation cohorts. Risk was converted into a 10-point scoring system.

The researchers found that in the testing and validation cohorts, PCCI score and age correlated with similar hazards of other-cause mortality. Equivalent risks were seen for each six-year increase in age at diagnosis of greater than 60 years and for one additional PCCI point. The age-adjusted PCCI scores were strongly predictive of other-cause mortality. For a score of 0, 1 to 2, 3 to 4, 5 to 6, 7 to 9, and 10+, the subhazard ratios of other-cause mortality versus 0 were 2.0, 4.0, 8.7, 14.7, and 43.2, respectively; 10-year cumulative incidence of other-cause mortality was 10, 19, 35, 60, 79, and 99 percent, respectively.

"The -adjusted PCCI strongly stratifies the risk of long-term, other-cause ," the authors write. "It may be incorporated into shared decision-making to decrease overtreatment of older and chronically ill men with cancer."

One author disclosed a financial tie to WiserCare.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Journal of Urology

Copyright © 2015 HealthDay. All rights reserved.

Citation: Age-adjusted comorbidity score stratifies mortality in prostate CA (2015, June 25) retrieved 28 March 2024 from https://medicalxpress.com/news/2015-06-age-adjusted-comorbidity-score-stratifies-mortality.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Benefit of aggressive prostate CA Tx weakens as comorbidity rises

7 shares

Feedback to editors